Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders.
The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 5,073,132, representing 43.57% of the Company’s 11,642,953 outstanding common shares entitled to be voted. All of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s Management Information Circular dated August 28, 2022, were approved by the requisite majority of votes cast at the Meeting.
Each of the nominee directors listed in the Circular was elected as a director to serve as a director of the Company until the Company’s next annual shareholders meeting or until his or her successor is duly elected or appointed. The detailed results of the vote are set out below:
| Name of Nominee | Votes cast
FOR | % Votes
FOR | Votes cast
AGAINST | % Votes
AGAINST |
| Joseph Del Moral | 4,024,527 | 92.38% | 332,123 | 7.62% |
| Ronan Levy | 3,443,643 | 79.04% | 913,007 | 20.96% |
| Hannan Fleiman | 4,025,665 | 92.40% | 330,985 | 7.60% |
| Helen M. Boudreau | 4,333,410 | 99.47% | 23,241 | 0.53% |
| Dieter Weinand | 4,331,861 | 99.43% | 24,790 | 0.57% |
| Ellen Lubman | 4,333,479 | 99.47% | 23,172 | 0.53% |
| Barry Fishman | 4,353,275 | 99.92% | 3,376 | 0.08% |
Ernst & Young LLP, Chartered Accountants, was re-appointed as the auditor of the Company (and to authorize the directors to fix their remuneration) until the next annual meeting of shareholders. The detailed results of the vote are set out below:
| Votes cast FOR | % Votes FOR | Votes WITHHELD | % Votes
WITHHELD |
|
| 5,049,937 | 99.54% | 23,193 | 0.46% |
In addition, the Company shareholders approved the adoption of the second amended and restated equity incentive plan of the Company. The detailed results of the vote are set out below:
| Votes cast FOR | % Votes FOR | Votes cast AGAINST | % Votes AGAINST |
| 3,434,366 | 78.83% | 922,284 | 21.17% |
About Reunion Neuroscience Inc
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.